InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results
August 09, 2018 07:00 ET
|
InflaRx N.V.
Received FDA clearance of IND for Phase II trial of IFX-1 in ANCA-associated vasculitisEstablished U.S. research facility to continue advancing complement-based researchCompletion of follow-on...
InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
June 28, 2018 07:30 ET
|
InflaRx N.V.
JENA, Germany, June 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by...
InflaRx Opens New Research Facility in Ann Arbor
June 05, 2018 07:30 ET
|
InflaRx N.V.
R&D activities will focus on proprietary complement scienceSite will be overseen by InflaRx Chief Scientific Officer JENA, Germany, June 05, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX),...
InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results
May 17, 2018 07:30 ET
|
InflaRx N.V.
Initiated international Phase IIb study of IFX-1 in Hidradenitis Suppurativa patients Completion of primary and secondary offering of US$117 million Cash position approximately US$137 million (€115...
InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares
May 08, 2018 10:42 ET
|
InflaRx N.V.
JENA, Germany, May 08, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement...
InflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares
May 03, 2018 20:28 ET
|
InflaRx N.V.
JENA, Germany, May 03, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement...
InflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares
May 02, 2018 07:44 ET
|
InflaRx N.V.
JENA, Germany, May 02, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement...
InflaRx Full Year 2017 Financial & Operating Results
March 29, 2018 07:00 ET
|
InflaRx N.V.
IFX-1 Positive Phase IIa data in Hidradenitis Suppurativa (HS) patients US$136 million Series D & Nasdaq IPO financings U.S. IND opened, international Phase IIb initiated for IFX-1 in HS...